“
TL;DR
It found that hypoglycemic conditions increased basal SIRT1 secretion, while hyperglycemic conditions decreased it, and that resveratrol could modulate SIRT1 levels under inflammatory stress.
International Journal of Molecular Sciences · 6 authors, 3 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
It found that hypoglycemic conditions increased basal SIRT1 secretion, while hyperglycemic conditions decreased it, and that resveratrol could modulate SIRT1 levels under inflammatory stress.
This preclinical study employed a two-component in vitro model of the blood-brain barrier (BBB) consisting of endothelial cells (microvascular compartment, MC) and astrocytes (brain compartment, BC) to investigate the interplay between systemic glycemia, neuroinflammation, and astrocyte SIRT1 response. They observed a correlation between MC glucose concentration and basal SIRT1 levels in the BC, with hypoglycemia associated with higher SIRT1 and hyperglycemia with lower SIRT1. Limitations noted by the authors include the model's exclusion of other key BBB components like pericytes and neurons, meaning the results cannot be directly generalized to in vivo human conditions. The implications are mechanistic, suggesting glycemic status may influence astrocytic SIRT1-mediated responses to neuroinflammation.